|Articles|June 6, 2013
From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Why Is Lung Health Key to Survivorship After Cancer Treatment?
2
New Combination Treatment Approach Studied in Pancreatic Cancer
3
Discussing Community and the Importance of World Cancer Day
4
U.S. Soccer Legend Kasey Keller Reveals Lymphoma Journey
5